Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,568
  • Shares Outstanding, K 24,080
  • Annual Sales, $ 10,140 K
  • Annual Income, $ -48,630 K
  • 60-Month Beta 0.28
  • Price/Sales 5.08
  • Price/Cash Flow N/A
  • Price/Book 0.44
Trade TCRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.73
  • Number of Estimates 4
  • High Estimate -0.63
  • Low Estimate -0.81
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.91 +6.81%
on 12/07/22
2.89 -29.41%
on 11/14/22
-0.49 (-19.37%)
since 11/09/22
3-Month
1.91 +6.81%
on 12/07/22
3.65 -44.11%
on 10/20/22
-1.26 (-38.18%)
since 09/09/22
52-Week
1.60 +27.50%
on 05/09/22
6.40 -68.13%
on 12/13/21
-4.22 (-67.41%)
since 12/09/21

Most Recent Stories

More News
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ADCT : 3.10 (+0.98%)
TCRX : 2.04 (-2.86%)
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify...

TCRX : 2.04 (-2.86%)
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 3.62 (-13.81%)
TCRX : 2.04 (-2.86%)
TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 2.04 (-2.86%)
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to...

TCRX : 2.04 (-2.86%)
TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 2.04 (-2.86%)
TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 2.04 (-2.86%)
TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 2.04 (-2.86%)
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101...

TCRX : 2.04 (-2.86%)
TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 2.04 (-2.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 2.37
2nd Resistance Point 2.28
1st Resistance Point 2.19
Last Price 2.04
1st Support Level 2.01
2nd Support Level 1.92
3rd Support Level 1.83

See More

52-Week High 6.40
Fibonacci 61.8% 4.57
Fibonacci 50% 4.00
Fibonacci 38.2% 3.43
Last Price 2.04
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar